Novartis got some more upbeat press earlier in the week when researchers on the Zolgensma gene therapy program outlined some updated biomarker data on their SMA drug and noted that 21 of 22 patients were alive and event free as of last fall. But it turns out there was a post script to the study that raises some safety concerns for the pharma giant’s therapy — recently acquired in an $8.7 billion acquisition of AveXis.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription